Fisetin for Senolytic Activity

In October 2018, the EBioMedicine journal published a paper by Matthew Yousefzadeh, Yi Zhu, James Kirkland, Paul Robbins, and colleagues at the Mayo Clinic that fundamentally reset attention on a previously obscure strawberry flavonoid. The team screened ten flavonoid compounds for the ability to selectively kill senescent cells while sparing healthy cells — an activity called “senolytic.” Fisetin won by a wide margin and was the only compound that produced lifespan extension in already-aged mice. Crucially, the magnitude was striking: median life-span extended by approximately ten percent, maximum lifespan by a similar margin, and frailty markers improved substantially — in mice that started treatment at 85 weeks of age (roughly equivalent to a 75-year-old human). Six years later, the Mayo Clinic AFFIRM and AFFIRM-LITE trials are testing whether the mouse-translated dose produces comparable effects in older humans. This deep-dive page walks through what senescent cells are, why they accumulate, how fisetin selectively eliminates them, the foundational 2018 paper, the broader senolytic research program around dasatinib + quercetin and navitoclax, and the honest framing of what the human evidence currently supports.

Table of Contents

1. What Senescent Cells Are — The Zombie Cell Primer
2. The SASP — Why a Few Senescent Cells Damage Whole Tissues
3. The Yousefzadeh 2018 EBioMedicine Paper
4. Mechanism — SCAPs and BCL-2/BCL-xL/BCL-W Inhibition
5. The Mayo Clinic Translational Program (Kirkland & Tchkonia)
6. The Dasatinib + Quercetin (D+Q) Cocktail Context
7. AFFIRM, AFFIRM-LITE, and Related Senolytic Trials
8. The “Hit and Run” Dosing Rationale
9. How to Measure Whether Fisetin Worked — Senescence Biomarkers
10. Honest Framing — The Animal-vs-Human Evidence Gap
11. Practical Context for Patients Considering Fisetin
12. Key Research Papers
13. Connections

What Senescent Cells Are — The Zombie Cell Primer

Cellular senescence is a state that cells enter when they are damaged beyond repair. The triggers are familiar: shortened telomeres after many cell divisions, irreparable DNA double-strand breaks, persistent oxidative stress, oncogene activation (paradoxically a defense against cancer transformation), and exposure to chemotherapy or radiation. A normal cell, when it cannot repair the damage, has two paths forward — apoptosis (clean, regulated cell death) or senescence (permanent withdrawal from the cell cycle).

The senescent path was originally thought to be safer than apoptosis from an organism-level perspective: a damaged cell that stops dividing cannot become cancerous, and a stopped cell is less disruptive than a sudden empty space in a tissue. This is correct in the short term and in young tissues. The problem is that senescent cells do not actually leave. They sit in place, they refuse to die (they over-express the anti-apoptotic proteins that protect them from programmed cell death), and they actively secrete a chemical cocktail that gradually poisons their neighborhood.

In a young tissue, the immune system clears senescent cells reasonably well — natural killer cells and macrophages can recognize and remove them. In an aging tissue, immune clearance falters, senescent-cell numbers rise, and the senescent-cell burden begins to drive its own pathology. Mouse experiments where senescent cells are genetically tagged with an inducible suicide gene have shown that simply removing the senescent cells, without any other intervention, extends healthspan, reduces frailty, improves cardiovascular function, and delays multimorbidity (Baker et al., Nature 2011 and 2016). This was the proof-of-concept that motivated the entire senolytics field.

Back to Table of Contents

The SASP — Why a Few Senescent Cells Damage Whole Tissues

The mechanism by which senescent cells damage surrounding tissue is the senescence-associated secretory phenotype or SASP. Senescent cells secrete a complex cocktail of:

• Pro-inflammatory cytokines — interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-1α, tumor necrosis factor alpha (TNF-α)
• Chemokines — CXCL1, CXCL10, MCP-1, that recruit additional immune cells and amplify local inflammation
• Matrix metalloproteinases (MMPs) — enzymes that degrade extracellular matrix and disrupt tissue architecture
• Growth factors — that can paradoxically promote nearby cancer cell proliferation
• Reactive oxygen species — that damage neighboring cells' DNA and proteins

The SASP's evolved purpose appears to be to summon immune cells to clear the damaged cell. But when immune clearance is impaired or when the senescent cell persists, the SASP becomes a chronic local inflammatory signal that:

1. Pushes nearby healthy cells toward senescence themselves (a paracrine spreading effect)
2. Degrades tissue architecture and barrier function
3. Contributes to systemic low-grade chronic inflammation (“inflammaging”)
4. Promotes insulin resistance, atherosclerosis, sarcopenia, and cognitive decline

A small number of senescent cells — estimated at one to two percent of cells in some aged tissues — can produce disproportionate tissue dysfunction through SASP amplification. This is why a senolytic that clears even a fraction of senescent cells can produce measurable functional improvements.

Back to Table of Contents

The Yousefzadeh 2018 EBioMedicine Paper

The seminal paper is Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, Ling YY, Melos KI, Pirtskhalava T, Inman CL, McGuckian C, Wade EA, Kato JI, Grassi D, Wentworth M, Burd CE, Arriaga EA, Ladiges WL, Tchkonia T, Kirkland JL, Robbins PD, Niedernhofer LJ. “Fisetin is a senotherapeutic that extends health and lifespan.” EBioMedicine 2018; 36: 18-28. The paper compared ten flavonoids for senolytic activity:

• Screen design — the team tested fisetin, quercetin, luteolin, rutin, myricetin, apigenin, kaempferol, catechin, epigallocatechin gallate (EGCG), and curcumin against senescent human umbilical vein endothelial cells (HUVECs), senescent mouse embryonic fibroblasts (MEFs), and primary cultures of human adipose-derived progenitors.
• Result — fisetin showed the highest senolytic activity. It selectively killed senescent cells with EC50 values approximately 5- to 10-fold lower than quercetin (the next-best compound) and showed minimal toxicity to non-senescent cells in the same cultures.
• Animal validation — fisetin treatment in progeroid (Ercc1^-/Δ) mice and in old wild-type C57BL/6 mice reduced senescent-cell burden across adipose tissue, kidney, liver, skeletal muscle, and pancreas as measured by p16^INK4a mRNA expression and senescence-associated β-galactosidase staining.
• Lifespan effect — aged mice treated with intermittent fisetin showed extended median lifespan by approximately ten percent and improved healthspan markers including grip strength, gait speed, and frailty index. Importantly, treatment began at 85 weeks of age — equivalent to a roughly 75-year-old human — meaning the benefit was demonstrated as a late-life intervention rather than lifelong supplementation.

The combination of late-life initiation, lifespan extension, and demonstrated senescent-cell reduction across multiple tissues was unusual for a natural product and triggered the wave of human trials currently in progress.

Back to Table of Contents

Mechanism — SCAPs and BCL-2/BCL-xL/BCL-W Inhibition

The biological basis for senolytic activity is that senescent cells survive by over-expressing anti-apoptotic proteins — the senescent-cell anti-apoptotic pathways or SCAPs. A normal cell with persistent DNA damage would die by apoptosis. A senescent cell escapes apoptosis by ramping up survival pathways:

• BCL-2 family — BCL-2, BCL-xL, BCL-W, MCL-1 (all bind and inactivate the pro-apoptotic BAX and BAK)
• PI3K / AKT survival signaling
• p53 / p21 cell-cycle arrest (this is what makes them senescent in the first place)
• HIF-1α metabolic adaptation
• HSP90 chaperone-mediated protein-folding rescue

The senolytic strategy is to inhibit multiple SCAPs simultaneously. A senescent cell is already chronically stressed, so even partial inhibition of its survival machinery tips it across the apoptosis threshold. A healthy cell with intact survival pathways and lower baseline stress can tolerate the same intervention with minimal injury.

Fisetin's known mechanisms in this context include:

• Direct inhibition of BCL-xL and BCL-W (the dominant survival factors in senescent endothelial and fibroblast cells)
• Inhibition of PI3K/AKT signaling (a parallel survival pathway)
• Activation of p38 MAPK stress kinase signaling that tips senescent cells toward apoptosis
• Promotion of autophagy (which can either rescue or kill stressed cells; in senescent cells the balance tips toward death)

The multi-target mechanism is part of why fisetin is more reliably senolytic than narrower inhibitors. The dedicated pharmacologic BCL-xL inhibitor navitoclax is highly senolytic but causes severe thrombocytopenia (platelets are exquisitely BCL-xL-dependent) and is therefore unusable as a long-term geroscience drug. Fisetin's broader mechanism gives it a wider therapeutic window.

Back to Table of Contents

The Mayo Clinic Translational Program (Kirkland & Tchkonia)

James Kirkland and Tamar Tchkonia at the Mayo Clinic Robert and Arlene Kogod Center on Aging have led the senolytic field translationally since the early 2010s. Their original 2015 Aging Cell paper (“The Achilles' heel of senescent cells”) introduced the SCAP concept and identified the first senolytic combination — dasatinib plus quercetin — by screening based on the predicted SCAP dependencies of senescent cells. The Yousefzadeh fisetin paper extended that screening approach to natural flavonoids.

The Mayo program operates through several converging lines:

1. Discovery — identifying new senolytic compounds by structure-based screening against predicted SCAP targets
2. Mechanism — determining which SCAPs each compound targets and which cell types are most vulnerable
3. Preclinical validation — demonstrating reduced senescent-cell burden and improved healthspan in aged or progeroid mice
4. First-in-human safety trials — AFFIRM and the original D+Q diabetic kidney disease and idiopathic pulmonary fibrosis trials
5. Efficacy trials — the larger AFFIRM-LITE and related programs testing functional endpoints (frailty, mobility, cognition) and disease endpoints (kidney function, pulmonary function, bone density)

The program is conservative in its public statements. Kirkland and Tchkonia consistently emphasize that the field is in the early translational phase, that current human data show changes in senescent-cell biomarkers but not yet in hard clinical endpoints, and that self-administration outside of clinical trials is premature. This honesty is striking against the backdrop of supplement-industry marketing that has substantially outrun the actual evidence.

Back to Table of Contents

The Dasatinib + Quercetin (D+Q) Cocktail Context

The first senolytic combination to enter human trials was dasatinib + quercetin (D+Q) — dasatinib is an FDA-approved tyrosine kinase inhibitor (used in chronic myeloid leukemia) and quercetin is a flavonol related to fisetin. The combination was identified by SCAP-based screening (dasatinib targets ephrin-dependent survival in senescent adipocytes; quercetin targets BCL-xL and PI3K/AKT in senescent endothelial cells). The two compounds together cover a broader range of senescent-cell types than either alone.

The pivotal early human studies were:

• Hickson et al. EBioMedicine 2019 — nine patients with diabetic kidney disease received three days of D+Q (100 mg dasatinib + 1000 mg quercetin) per week for three weeks. Adipose tissue biopsies showed reduced senescent-cell markers (p16^INK4a, p21^CIP1) and reduced SASP cytokines (IL-1α, IL-6, MCP-1) post-treatment. This was the first demonstration that a senolytic regimen could reduce senescent-cell burden in humans.
• Justice et al. EBioMedicine 2019 — fourteen patients with idiopathic pulmonary fibrosis received three weeks of intermittent D+Q. Physical function (6-minute walk distance, gait speed, chair stand) improved meaningfully over the treatment period.

Fisetin's appeal in this context is twofold. First, it is a single agent with similar or better senolytic potency to D+Q in mouse models. Second, dasatinib is a prescription chemotherapy drug with significant side effects (fluid retention, hematologic toxicity, QT prolongation), while fisetin is a food-derived flavonoid available without prescription. If the human efficacy data eventually confirm what the mouse data predict, fisetin would be substantially easier to deploy than D+Q.

Back to Table of Contents

AFFIRM, AFFIRM-LITE, and Related Senolytic Trials

The Mayo Clinic AFFIRM trial (Alleviation by Fisetin of Frailty, Inflammation, and Related Measures) is the lead human study of fisetin as a senolytic. AFFIRM-LITE is a smaller pilot of the same protocol in a subset of older adults. The study design follows the “hit and run” logic:

• Dose — approximately 20 mg/kg body weight (about 1500 mg for a 75 kg adult) on each of two consecutive days
• Schedule — the two-day course is repeated every 28-35 days
• Endpoints — primary endpoints include changes in senescent-cell markers in adipose tissue biopsy and in circulating inflammatory cytokines; secondary endpoints include frailty index, gait speed, grip strength, and bone density
• Population — older adults (typically >70 years) with at least one frailty marker

Beyond AFFIRM, fisetin is being studied in:

• Chronic kidney disease (Mayo Clinic and University of Texas)
• Diabetic kidney disease
• Knee osteoarthritis (multiple sites)
• Post-chemotherapy senescent-cell burden (oncology survivorship trials)
• Frailty in nursing-home populations

The ClinicalTrials.gov registry lists approximately twenty active or recently-completed fisetin trials. Most are small (10-100 participants), early-phase, and biomarker-focused. The published results to date show measurable changes in senescent-cell markers and inflammatory cytokines, with functional endpoints showing trends in the predicted direction but not yet reaching the rigor of large randomized trial outcomes.

Back to Table of Contents

The “Hit and Run” Dosing Rationale

Conventional pharmacology assumes that drug efficacy requires sustained plasma levels above some therapeutic threshold — the logic behind daily dosing of statins, blood-pressure medications, and antibiotics. Senolytics are different. The biological rationale for intermittent “hit and run” dosing is:

1. Senescent cells accumulate slowly — over weeks to months, not hours or days. Continuous suppression is not needed.
2. A single course of senolytic kills the existing senescent-cell burden — once killed, those cells are gone. The senolytic drug is no longer needed until new senescent cells re-accumulate.
3. Intermittent dosing reduces side-effect exposure — off-target effects are limited to the brief treatment period rather than chronic.
4. Intermittent dosing avoids tachyphylaxis — pathways that might adapt to continuous suppression remain responsive when re-challenged after weeks of washout.

For fisetin specifically, the typical research regimen is 20 mg/kg body weight on each of two consecutive days, repeated every 28-35 days. The two-day course gives the drug time to act on the senescent-cell population without the daily-dosing-rationale that would apply to a sustained-action drug. A 75 kg (165 lb) adult on the research regimen would take approximately 1500 mg on day 1, 1500 mg on day 2, and then nothing for four weeks.

Commercial fisetin supplements typically come in 100-500 mg capsules, so the research dose requires three to fifteen capsules taken with a fat-containing meal. Practical implementation varies widely — some users follow the research protocol verbatim, others use lower daily doses (100-200 mg) on a continuous basis, and still others use the two-day pulsed protocol but at lower doses (200-500 mg per dose). The pulsed approach has the strongest mechanistic rationale; the continuous low-dose approach has the weakest.

Back to Table of Contents

How to Measure Whether Fisetin Worked — Senescence Biomarkers

One of the practical challenges of self-administering senolytics is that there is no easy clinical biomarker for senescent-cell burden. The research-grade measurements include:

• p16^INK4a mRNA expression in tissue biopsy — the gold standard, but requires invasive sampling
• Senescence-associated β-galactosidase staining — classic but tissue-based
• SASP cytokine panel — circulating IL-6, IL-8, MCP-1, TNF-α (these are available commercially but are not specific to senescent cells; chronic infection and autoimmune disease elevate them too)
• GDF-15 (growth differentiation factor 15) — a circulating marker that correlates loosely with senescent-cell burden and is commercially available
• Klotho — decreases with senescent-cell accumulation; commercially available test

For consumers without access to clinical research infrastructure, the practical surrogates are functional — grip strength, six-minute walk distance, sleep quality, joint stiffness, recovery from exertion. These are non-specific but if a senolytic protocol is producing real effects, they should trend favorably over months of intermittent dosing. They are also the endpoints that matter clinically — biomarker changes that do not translate to functional improvement are not particularly meaningful.

For more on aging biomarkers and longevity testing, see our Biological Age testing page and our broader Longevity Protocols page.

Back to Table of Contents

Honest Framing — The Animal-vs-Human Evidence Gap

The honest summary of the fisetin senolytic evidence is that the preclinical case is one of the strongest in modern geroscience, while the human evidence remains preliminary. Specifically:

• The mouse data — striking. Multiple independent labs have replicated the Yousefzadeh findings of reduced senescent-cell burden and improved healthspan markers in aged or progeroid mice given intermittent fisetin. The lifespan-extension effect has been replicated in some strains and partially replicated in others. The animal evidence justifies the clinical translation effort.
• The human biomarker data — promising. Small pilot studies have shown reductions in senescent-cell markers in adipose biopsy and circulating SASP cytokines after intermittent fisetin or D+Q. These are not yet from large randomized trials.
• The human efficacy data — not yet. No large randomized trial has demonstrated that fisetin produces meaningful improvements in clinically relevant endpoints (frailty index, fracture rate, cognitive decline, all-cause mortality) compared to placebo. The AFFIRM trial and its successors are designed to answer this question and are ongoing.
• The supplement marketing — substantially ahead of the evidence. Online claims that fisetin is a proven longevity intervention, that it “reverses aging,” or that it is “the most-studied senolytic” outrun what the published clinical literature supports. The actual position is that fisetin is the most-promising flavonoid senolytic identified in preclinical screens, with preliminary human biomarker data and pending efficacy trials.

The cautious position for consumers is to either wait for the AFFIRM-LITE results or to participate in a clinical trial. The intermediate position is intermittent use of the published research protocol with the understanding that long-term safety and efficacy are not fully established. The over-aggressive position is daily high-dose use without clinical trial enrollment or biomarker monitoring — the position currently being marketed to consumers by some supplement vendors.

Back to Table of Contents

Practical Context for Patients Considering Fisetin

For patients in the longevity-curious population who are interested in fisetin despite the preliminary state of the human evidence, the relevant practical considerations are:

• Form — the Novusetin phytosome formulation has the most published bioavailability data and is what the Mayo Clinic studies use. Generic fisetin powder has substantially lower absorption. Liposomal preparations have small-study support.
• Dose — the research protocol is 20 mg/kg body weight on each of two consecutive days per month. A 75 kg adult would take approximately 1500 mg per day for two days, then nothing for four weeks. Some users start at 50 percent of this dose and titrate up.
• Timing — with a fat-containing meal (yogurt, olive oil, whole eggs) for absorption. Some studies co-administer with bromelain or piperine to enhance absorption.
• Contraindications — pregnancy, breastfeeding, active cancer treatment (theoretical chemotherapy interactions), and within two weeks of major surgery (mild antiplatelet effect). Caution with warfarin, DOACs, and other anticoagulants. Discuss with a clinician before starting if any chronic condition exists.
• Stack interactions — quercetin (similar mechanism, additive senolytic effect), curcumin (mild senolytic and anti-inflammatory), rapamycin (mTOR-inhibitor, complementary mechanism). Do not stack with prescription dasatinib or navitoclax outside of clinical trial supervision.
• Monitoring — baseline CBC, comprehensive metabolic panel, hsCRP, and optionally a SASP cytokine panel (IL-6, GDF-15, klotho). Repeat at 6 and 12 months.

The senolytic application is one of several plausible reasons to take fisetin. For the neuroprotective applications — which have a longer history and arguably better-established mechanisms in animal models — see our Fisetin Brain Health page. For the broader anti-aging context including mitochondrial and AMPK effects, see our Fisetin Anti-Aging page.

Back to Table of Contents

Key Research Papers

1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. (2018). Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36:18-28. — PubMed
2. Zhu Y, Tchkonia T, Pirtskhalava T, et al. (2015). The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14:644-658. — PubMed
3. Kirkland JL, Tchkonia T (2020). Senolytic drugs: from discovery to translation. Journal of Internal Medicine 288:518-536. — PubMed
4. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. (2019). Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine 47:446-456. — PubMed
5. Justice JN, Nambiar AM, Tchkonia T, et al. (2019). Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine 40:554-563. — PubMed
6. Xu M, Pirtskhalava T, Farr JN, et al. (2018). Senolytics improve physical function and increase lifespan in old age. Nature Medicine 24:1246-1256. — PubMed
7. Baker DJ, Wijshake T, Tchkonia T, et al. (2011). Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479:232-236. — PubMed
8. Baker DJ, Childs BG, Durik M, et al. (2016). Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. Nature 530:184-189. — PubMed
9. Kirkland JL, Tchkonia T (2017). Cellular senescence: a translational perspective. EBioMedicine 21:21-28. — PubMed
10. van Deursen JM (2014). The role of senescent cells in ageing. Nature 509:439-446. — PubMed
11. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL (2013). Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. Journal of Clinical Investigation 123:966-972. — PubMed
12. Coppe JP, Desprez PY, Krtolica A, Campisi J (2010). The senescence-associated secretory phenotype: the dark side of tumor suppression. Annual Review of Pathology 5:99-118. — PubMed

PubMed Topic Searches

• PubMed: Fisetin senolytic clinical trial
• PubMed: AFFIRM fisetin trials
• PubMed: SCAPs and senescent-cell biology
• PubMed: D+Q senolytic cocktail
• PubMed: SASP cytokine profile
• ClinicalTrials.gov — Active fisetin trials

Back to Table of Contents

Connections

• Fisetin Overview
• Fisetin Benefits Hub
• Fisetin Brain Health & Cognition
• Fisetin Anti-Aging
• Fisetin Inflammation & Allergy
• Quercetin (D+Q Cocktail Partner)
• Spermidine (Autophagy Inducer)
• Longevity Protocols
• Rapamycin (mTOR Inhibitor)
• NAD+ and NMN
• Kidney Disease
• Pulmonary Fibrosis
• Diabetes
• Osteoporosis
• Oxidative Stress

Back to Table of Contents